Sarepta Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2024, the Michael A. Chambers Living Trust, an affiliate of Michael Chambers, entered into andadopted a written plan for the sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information (a “Rule 10b5-1 trading plan”). Mr. Chambers' 10b5-1 trading plan has an adoption date of December 16, 2024 and an end date of September 12, 2025, covering 88,286 shares of common stock. As of the date of this Annual Report, Mr. Chambers beneficially owns 292,311 shares of common stock, inclusive of the shares of common stock underlying the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.